Clinic
Prime Healthcare Services - ST Michaels LLC
Prime Healthcare Services - ST Michaels LLC was paid $67.67M by Medicaid between Jan 2018 and Dec 2024, across 299 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES - ST MICHAELS LLC
NEWARK, NJ 07102
NEWARK, NJ 07102
33aNPI1568825545assigned 03/29/2016
33bProvider typeEnd-Stage Renal Disease (ESRD) Treatment Clinic/Center
28Total paid$67.67M
24GClaims1,460,408
24DCodes billed299
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other End-Stage Renal Disease (ESRD) Treatment Clinic/Center providers in New Jersey
Rank by total paid#1 of 192
Median peer was paid$1.42M
This provider vs. median48×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 207,622 | $13.57M | |
| 2019 | 210,013 | $12.39M | |
| 2020 | 150,603 | $6.45M | |
| 2021 | 227,041 | $10.71M | |
| 2022 | 232,354 | $9.01M | |
| 2023 | 253,907 | $8.30M | |
| 2024incomplete | 178,868 | $7.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 50,749 | 43,683 | $10.20M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 38,228 | 35,162 | $9.39M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 32,461 | 29,404 | $9.29M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 5,961 | 5,539 | $2.67M |
| OP370 | 3.5% | 11,778 | 10,200 | $2.39M | |
| OP272 | 3.0% | 61,345 | 50,307 | $2.04M | |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 9,884 | 9,146 | $1.65M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 3,540 | 3,275 | $1.35M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 29,681 | 25,265 | $1.33M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.9% | 2,795 | 2,510 | $1.26M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 13,282 | 12,041 | $946K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 22,542 | 18,951 | $872K |
287 more codes
| OP271 | 1.2% | 67,756 | $811K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.1% | 1,502 | $774K |
| G0378 | Hospital observation service, per hour | 1.0% | 2,981 | $704K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 33,173 | $654K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,780 | $631K |
| 71045 | Radiologic examination, chest; single view | <1% | 20,215 | $618K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,636 | $616K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,864 | $603K |
| 93458 | <1% | 670 | $587K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,748 | $579K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,903 | $557K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,994 | $515K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,398 | $503K |
| 80053 | Comprehensive metabolic panel | <1% | 54,500 | $474K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 20,013 | $462K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,025 | $451K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,428 | $435K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,869 | $422K |
| OP250 | <1% | 128,850 | $421K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 15,815 | $417K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 972 | $412K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,572 | $408K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 715 | $398K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,977 | $387K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,780 | $384K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 63,661 | $360K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,364 | $328K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,261 | $325K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,594 | $323K |
| 73630 | <1% | 4,209 | $289K | |
| 84484 | <1% | 24,272 | $271K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,911 | $256K |
| 76830 | Ultrasound, transvaginal | <1% | 2,076 | $242K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,630 | $226K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 13,046 | $226K |
| 73130 | <1% | 2,751 | $210K | |
| 70486 | <1% | 1,147 | $210K | |
| 73030 | <1% | 3,054 | $209K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,776 | $209K |
| 72110 | <1% | 2,852 | $203K | |
| OP710 | <1% | 4,107 | $196K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,827 | $195K |
| 83690 | <1% | 24,535 | $186K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,374 | $183K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 492 | $181K |
| 83880 | <1% | 6,925 | $177K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 11,353 | $169K |
| 88342 | <1% | 3,266 | $163K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 39,405 | $156K |
| 96367 | <1% | 2,194 | $147K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 3,782 | $147K |
| 76642 | <1% | 1,443 | $143K | |
| 73564 | <1% | 2,056 | $140K | |
| 73610 | <1% | 2,822 | $138K | |
| 93970 | <1% | 892 | $135K | |
| J3490 | Unclassified drugs | <1% | 29,614 | $134K |
| 93017 | <1% | 850 | $126K | |
| 81025 | <1% | 37,056 | $124K | |
| 87186 | <1% | 3,400 | $121K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 334 | $112K |
| 93971 | <1% | 1,173 | $104K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,837 | $104K |
| J2704 | Injection, propofol, 10 mg | <1% | 10,323 | $97K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,624 | $95K |
| 77066 | Tomosynthesis, mammo | <1% | 841 | $90K |
| 77065 | Tomosynthesis, mammo | <1% | 1,049 | $88K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 30,591 | $87K |
| C1769 | Guide wire | <1% | 1,255 | $87K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,834 | $82K |
| 71250 | <1% | 586 | $81K | |
| 80320 | <1% | 4,811 | $81K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,414 | $79K |
| 72131 | <1% | 353 | $79K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,685 | $79K |
| 73110 | <1% | 1,099 | $79K | |
| 77080 | <1% | 1,415 | $78K | |
| OP270 | <1% | 13,355 | $78K | |
| 73562 | <1% | 1,953 | $72K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,609 | $65K |
| 82962 | <1% | 18,431 | $65K | |
| 90714 | <1% | 2,079 | $63K | |
| 87040 | <1% | 4,455 | $61K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 22,881 | $56K |
| V2632 | Posterior chamber intraocular lens | <1% | 808 | $55K |
| 83605 | <1% | 5,386 | $55K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 503 | $55K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 381 | $47K |
| 96417 | <1% | 366 | $47K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,219 | $45K |
| 73502 | <1% | 1,291 | $43K | |
| 90837 | Psychotherapy session, about an hour | <1% | 731 | $43K |
| 76801 | <1% | 375 | $42K | |
| 87420 | <1% | 3,380 | $41K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 170 | $41K |
| 72100 | <1% | 514 | $40K | |
| 81001 | <1% | 22,333 | $39K | |
| 99406 | <1% | 6,830 | $39K | |
| 86900 | <1% | 3,104 | $39K | |
| 72050 | <1% | 637 | $38K | |
| 82550 | <1% | 7,146 | $38K | |
| 76641 | <1% | 172 | $37K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 374 | $37K |
| 77062 | <1% | 362 | $35K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,734 | $34K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 949 | $32K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,125 | $32K |
| 85379 | <1% | 3,615 | $32K | |
| 86850 | <1% | 2,625 | $32K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,090 | $32K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 53 | $30K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,044 | $29K |
| 83735 | <1% | 10,280 | $29K | |
| 84702 | <1% | 2,994 | $28K | |
| 82728 | <1% | 2,977 | $28K | |
| 73590 | <1% | 429 | $27K | |
| OP278 | <1% | 182 | $27K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,881 | $26K |
| 87077 | <1% | 3,144 | $25K | |
| 85610 | <1% | 9,101 | $25K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 1,738 | $24K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,041 | $24K |
| 85730 | <1% | 8,008 | $23K | |
| 87449 | <1% | 3,049 | $23K | |
| 84100 | <1% | 9,457 | $22K | |
| 80061 | Lipid panel | <1% | 2,104 | $22K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,073 | $22K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 271 | $22K |
| 86901 | <1% | 3,153 | $21K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,909 | $21K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,731 | $20K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,605 | $20K |
| 96376 | <1% | 1,035 | $19K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,517 | $18K |
| 74018 | <1% | 442 | $18K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,295 | $18K |
| 94762 | <1% | 755 | $17K | |
| 81003 | <1% | 11,065 | $16K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 596 | $15K |
| 84145 | <1% | 812 | $15K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,501 | $15K |
| 73080 | <1% | 289 | $14K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,864 | $14K |
| 71101 | <1% | 277 | $13K | |
| 82607 | <1% | 1,586 | $13K | |
| 71111 | <1% | 210 | $13K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 73 | $12K |
| 82947 | <1% | 2,109 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,206 | $12K |
| 83550 | <1% | 2,537 | $11K | |
| 77336 | <1% | 204 | $11K | |
| 80329 | <1% | 353 | $11K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 213 | $10K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,701 | $10K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,323 | $10K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,230 | $10K |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 780 | $10K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 305 | $10K |
| 76536 | <1% | 90 | $9K | |
| OP259 | <1% | 289 | $9K | |
| 83540 | <1% | 2,554 | $9K | |
| 74022 | <1% | 146 | $9K | |
| 95811 | <1% | 14 | $9K | |
| 83615 | <1% | 3,342 | $8K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 5,708 | $8K |
| 96402 | <1% | 117 | $8K | |
| 82746 | <1% | 767 | $8K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,875 | $7K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,716 | $7K |
| 86140 | <1% | 1,480 | $7K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 638 | $7K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,728 | $6K |
| 73140 | <1% | 112 | $6K | |
| 88300 | <1% | 905 | $6K | |
| 96415 | <1% | 76 | $6K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 67 | $6K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 72 | $6K |
| A4606 | Oxygen probe for use with oximeter device, replacement | <1% | 498 | $6K |
| 77061 | <1% | 86 | $6K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,314 | $5K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 140 | $5K |
| 86703 | <1% | 365 | $5K | |
| 86300 | <1% | 309 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,399 | $5K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 804 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 481 | $4K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 159 | $4K |
| 88304 | <1% | 116 | $4K | |
| 73090 | <1% | 55 | $4K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 5,237 | $3K |
| 12001 | <1% | 53 | $3K | |
| 73560 | <1% | 51 | $3K | |
| 80047 | <1% | 817 | $3K | |
| 10060 | <1% | 37 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,391 | $3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 111 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 104 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 994 | $3K |
| 80074 | <1% | 91 | $3K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 322 | $3K |
| 76775 | <1% | 24 | $3K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 19 | $3K |
| 97161 | <1% | 57 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 50 | $3K |
| 82010 | <1% | 442 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,699 | $2K |
| 72040 | <1% | 63 | $2K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 32 | $2K |
| 29125 | <1% | 39 | $2K | |
| 85651 | <1% | 814 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 334 | $2K |
| 77085 | <1% | 21 | $1K | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 43 | $1K |
| 85027 | <1% | 474 | $1K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 877 | $1K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 361 | $1K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 283 | $1K |
| 36430 | <1% | 12 | $1K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,810 | $1K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 204 | $1K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 13 | $1K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 14 | $975.00 |
| 76870 | <1% | 12 | $968.40 | |
| A4223 | Infusion supplies not used with external infusion pump, per cassette or bag (list drugs separately) | <1% | 423 | $961.66 |
| 71271 | <1% | 28 | $952.35 | |
| 85044 | <1% | 299 | $842.33 | |
| 81005 | <1% | 398 | $809.50 | |
| A6531 | Gradient compression stocking, below knee, 30-40 mmhg, used as a surgical dressing, each | <1% | 99 | $795.20 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 631 | $753.89 |
| 94760 | <1% | 62 | $722.17 | |
| 82378 | <1% | 75 | $692.85 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 342 | $686.28 |
| 84439 | <1% | 69 | $659.43 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 232 | $654.30 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 160 | $643.65 |
| J1097 | Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml | <1% | 14 | $619.49 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 222 | $617.70 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 78 | $590.16 |
| 82805 | <1% | 73 | $580.03 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 334 | $538.78 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 12 | $532.09 |
| OP274 | <1% | 260 | $519.08 | |
| J0706 | Injection, caffeine citrate, 5 mg | <1% | 30 | $512.15 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 229 | $499.16 |
| 73552 | <1% | 15 | $468.69 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 683 | $468.13 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 374 | $461.93 |
| 90656 | <1% | 19 | $459.08 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 95 | $419.19 |
| 83010 | <1% | 42 | $403.49 | |
| 72074 | <1% | 14 | $355.40 | |
| A4556 | Electrodes, (e.g., apnea monitor), per pair | <1% | 353 | $353.09 |
| 82270 | <1% | 60 | $343.77 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 189 | $320.33 |
| 82784 | <1% | 21 | $276.34 | |
| A4930 | Gloves, sterile, per pair | <1% | 69 | $257.20 |
| 87299 | <1% | 30 | $257.14 | |
| 80076 | <1% | 125 | $236.53 | |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 127 | $220.61 |
| 87070 | <1% | 16 | $184.10 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 44 | $174.70 |
| 85007 | <1% | 395 | $162.72 | |
| A6450 | Light compression bandage, elastic, knitted/woven, width greater than or equal to five inches, per yard | <1% | 118 | $151.84 |
| A4927 | Gloves, non-sterile, per 100 | <1% | 54 | $149.99 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 55 | $148.26 |
| 87340 | <1% | 15 | $141.84 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 180 | $140.19 |
| 86803 | <1% | 12 | $137.37 | |
| 86706 | <1% | 14 | $121.56 | |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 104 | $117.36 |
| 87205 | <1% | 18 | $91.47 | |
| 84550 | <1% | 15 | $84.22 | |
| OP255 | <1% | 13 | $78.65 | |
| OP258 | <1% | 14 | $77.72 | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 32 | $63.08 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 48 | $60.16 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 48 | $56.63 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 35 | $50.37 |
| A4928 | Surgical mask, per 20 | <1% | 31 | $40.77 |
| A4452 | Tape, waterproof, per 18 square inches | <1% | 13 | $37.05 |
| A4657 | Syringe, with or without needle, each | <1% | 50 | $34.88 |
| 86592 | <1% | 15 | $28.80 | |
| A6216 | Gauze, non-impregnated, non-sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 69 | $24.76 |
| A6443 | Conforming bandage, non-elastic, knitted/woven, non-sterile, width greater than or equal to three inches and less than five inches, per yard | <1% | 24 | $16.90 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 23 | $10.00 |
| OP257 | <1% | 22 | $8.06 | |
| 99215 | Doctor's office visit, returning patient (complex) | 0% | 130 | $0.00 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 0% | 100 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (CHIEF COMPLIANCE COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.